Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Fatigue, Somnolence and Depression Persist After Six Month In Recovered Individual After The Acute Covid-19
General Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
12-003

Neuropsychiatric symptoms may persist after the COVID-19 infection.

To assess depression/anxiety symptoms, fatigue and daytime sleepiness in individuals previously affected by the COVID-19 infection.

We included 1183 cases of post-Covid infection (79% women; median age 41 [12-77]) who answered an interview of our online survey (median interval 191 days [50-503] after the infection). We used the Hamilton Anxiety and Depression Scale to evaluate anxiety (HADS-A) and depression symptoms (HADS-D), the Chalder Fatigue Scale to measure the fatigue severity and the Epworth Sleepiness Scale to assess daytime sleepiness. Individuals also answered the PHQ-9 (Patient Health Questionnaire-9). Patients were separated according to the treatment type (home [1046, median 41 years], ward [87, median 45.5 years] or ICU [50, median 48.5 years]). We performed Mann-Whitney tests to compare continuous variables among groups and Spearman tests for correlations.

Anxiety symptoms were more severe in ICU patients (median score 12 [0-19]) compared to the home group (median score 9 [0-21]; p=0.012). Similarly, the severity of physical fatigue was higher in the patients treated in ICU (median score 16 [2-21]) compared to home treatment (median score 13 [0-21]; p=0.004). However, the depression severity (p=0.1), PHQ-9 scores (p=0.06), mental fatigue (p=0.06) and daytime sleepiness scores (p=0.6) were similar among the three groups. Overall, there were positive correlations between sleepiness and both mental (r=0.33, p<0.001) and physical fatigue (r=0.44, p<0.001). The PHQ-9 scores positively correlated with sleepiness (r=0.36, p<0.001), mental fatigue (r=0.63, p<0.001) and physical fatigue (r=0.73, p<0.001). Interestingly, these correlations were present for the three groups, even after splitting according to treatment.

We confirmed persistent symptoms of fatigue, daytime sleepiness, anxiety and depression in a large group of recovered individuals after six months from the acute infection. Surprisingly, patients with mild infection presented equivalent intensity of mental fatigue, somnolence and depression, compared to those who required hospitalization.

Authors/Disclosures
Rafael Joao
PRESENTER
Mr. Joao has nothing to disclose.
Lucas Scárdua Silva, MD (University of Campinas) Dr. Silva has nothing to disclose.
Alex De Castro Carvalho (UNICAMP) Mr. Carvalho has nothing to disclose.
Italo Karmann Aventurato, MD Dr. Karmann Aventurato has received research support from Coordenadoria de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES). Dr. Karmann Aventurato has received research support from Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP).
Beatriz Costa (University of Campinas) Miss Costa has nothing to disclose.
Mariana Rabelo De Brito, MD (Hospital De Clinicas Da Unicamp) No disclosure on file
Mateus Nogueira Mateus Nogueira has nothing to disclose.
Marina Koutsodontis Alvim (Hospital Das Clinicas Unicamp) Dr. Alvim has nothing to disclose.
Fernando Cendes, MD, PhD, FAAN (Departamento de Neurologia; FCM; UNICAMP) Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH.
Clarissa L. Yasuda, MD, PhD (University of Campinas) Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for LIBBS. Prof. Yasuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBOTT. Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for LIBBS.